@Article{or.2024.050851,
AUTHOR = {RONG LIU, SHENG LI, SITU XIONG, FUCUN ZHENG, XIANGPENG ZHAN, JIN ZENG, BIN FU, SONGHUI XU, SHAOXING ZHU, RU CHEN},
TITLE = {Integrative bioinformatics and <i>in vitro</i> exploration of EVI2A expression: unraveling its immunological and prognostic implications in kidney renal clear cell carcinoma},
JOURNAL = {Oncology Research},
VOLUME = {32},
YEAR = {2024},
NUMBER = {11},
PAGES = {1733--1746},
URL = {http://www.techscience.com/or/v32n11/58379},
ISSN = {1555-3906},
ABSTRACT = {EVI2A has emerged as a significant biomarker in various diseases; however, its biological role and mechanism in kidney renal clear cell carcinoma (KIRC) remains unexplored. We used TCGA and GEO databases to analyze EVI2A gene expression comprehensively and performed pan-cancer assessments. Clinical relevance was evaluated through Kaplan-Meier analysis and ROC curves. The gene’s immune relevance was explored through analyses of the tumor microenvironment (TME), Tumor Immune Single-cell Hub (TISCH), immune checkpoints, and immunotherapy sensitivity. Our results indicate that EVI2A expression is upregulated in KIRC, showing correlations with tumor grade and T/N/M stage. EVI2A demonstrates high diagnostic accuracy (AUC=0.906) and predicts poor overall and progression-free survival in KIRC patients. Furthermore, EVI2A expression exhibits significant associations with immunity, including TME scores and specific immune cell types such as Tfh cells, CD4 memory T cells, and CD8+ T cells. Elevated EVI2A expression suggests increased sensitivity to PD-1/CTLA-4 and tyrosine kinase inhibitors. <i>In vitro</i> assays confirmed the impact of EVI2A on KIRC behavior, with its knockdown resulting in reduced cell proliferation and migration. In conclusion, our comprehensive analysis identifies EVI2A as a promising biomarker and a novel therapeutic target for intervening in KIRC. These findings hold significant implications for further research and potential clinical applications.},
DOI = {10.32604/or.2024.050851}
}